Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
Lipoprotein(a) [Lp(a)] is a unique lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B-100 of an LDL-like particle.1,2 The strong and consistent genetic and epidemiological evidence of elevated Lp(a) as an independent risk factor for cardiovascular disease and aortic stenosis has generated intense interest in developing novel therapies to lower plasma levels.3 Due to the fact that Lp(a) levels are primarily determined by the synthetic rate of apolipoprotein(a) in hepatocytes, liver-targeted therapies are ideally suited to treat elevated Lp(a).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Ewa Karwatowska ‑Prokopczuk, Anastasia Lesogor, Jing-He Yan, Eunju Hurh, Angelika Hoenlinger, Alison Margolskee, Shuting Xia, Sotirios Tsimikas Tags: Original Research Source Type: research
More News: Aortic Stenosis | Cardiology | Cardiovascular | Epidemiology | Genetics | Heart | Japan Health | Lipidology | Liver | Urology & Nephrology